Interpretation of changes in circulating tumor cell counts

Translational Oncology

Volumn 5, Issue 6, 2012, Pages 486-491

  Coumans, Frank A W ^a   Ligthart, Sjoerd T ^a   Terstappen, Leon W M M ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4', 6 DIAMIDINO 2 PHENYLINDOLE; CYTOKERATIN; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; STATISTICAL ANALYSIS;

EID: 84871698282     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12247     Document Type: Article

References (21)

1. Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, Clack G, Malone M, Coumans FA, and Terstappen LW (2011). Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38, 755-760.
2. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351, 781-791.
3. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26, 3213-3221.
4. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, and Raghavan D (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castrationresistant prostate cancer. Clin Cancer Res 14, 6302-6309.
5. Matsusaka S, Chin K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, and Hatake K (2010). Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci 101, 1067-1071.
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, et al. (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29, 1556-1563.
7. Hiltermann TJN, Liesker JJW, van den Berg A, Schouwink JH, Wijnands WJA, Kerner GSMA, Boezen HM, Pore MM, Kruyt FAE, Timens W, et al. (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. DOI: 10.1093/annonc/mds138.
8. Hayes DF (2006). Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12, 4218-4224.
9. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWMM, et al. (2006). Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12, 6403-6409.
10. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, et al. (2010). Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21, 33-39.
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, and Terstappen L (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10, 6897-6904.
12. Scher HI, Jia XY, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, and Heller G (2009). Circulating tumour cells as prognostic markers in progressive, castrationresistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10, 233-239.
13. Tibbe AGJ, Miller MC, and Terstappen LWMM (2007). Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71A, 154-162.
14. Coumans FAW, Ligthart ST, Uhr J, and Terstappen LWMM (2012). Challenges in the enumeration and phenotyping ofCTC. Clin Can Res. DOI: 10.1158/1078-0432.
15. de Groot MR, Croonen HM, Mastboom WJT, Vermes I, Tibbe AGJ, Tissing H, and Terstappen LWMM (2007). Circulating tumor cells (CTC) in newly diagnosed breast or colorectal cancer. Proc Annu Meet Am Soc Clin Oncol 25, 18S:14512.
16. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 13, 920-928.
17. Yagata H, Nakamura S, Toi M, Bando H, Ohno S, and Kataoka A (2008). Evaluation of circulating tumor cells in patients with breast cancer: multiinstitutional clinical trial in Japan. Int J Clin Oncol 13, 252-256.
18. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, and Pierga JY (2010). Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21, 729-733.
19. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, et al. (2007). Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13, 2023-2029.
20. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, et al. (2009). Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27, 5153-5159.
21. Krebs MG, Hou J-M, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, et al. (2012). Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial markerdependent and-independent approaches. J Thorac Oncol 7, 306-315.